On July 5, 2007, Buettelmann, Bernd; Han, Bo; Knust, Henner; Thomas, Andrew published a patent.SDS of cas: 386704-04-7 The title of the patent was Preparation of arylisoxazolyl imidazoles as GABAA α5 receptor ligands for the treatment of cognitive disorder and Alzheimer’s disease. And the patent contained the following:
Title compounds I [wherein R1, R2, R3 = H or halo; R4 = H, alkyl, cycloalkyl, etc.; R5 = (un)substituted (CH2)m-(hetero)aryl; m = 0-1; R6 = H, CHO, cycloalkyl, etc.] and pharmaceutically acceptable acid addition salts thereof were prepared as GABAA α5 receptor ligands. For instance, II was synthesized in 43% yield by N-alkylation of the corresponding imidazole with 4-fluoroacetophenone. This compound has a Ki value of 4.7 nM for displacement of [3H]flumazenil from GABAA α5 subunits. I and their pharmaceutical compositions are useful for the treatment of diseases related to the GABAA a5 subunits, such as cognitive disorder and Alzheimer’s disease. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).SDS of cas: 386704-04-7
The Article related to arylisoxazolyl imidazole preparation gabaa receptor ligand cognitive enhancer antialzheimer, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.SDS of cas: 386704-04-7
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts